Z 160
Alternative Names: MK-6721; NMED-160; Z160Latest Information Update: 15 Nov 2013
At a glance
- Originator Neuromed Pharmaceuticals
- Developer Neuromed Pharmaceuticals; Zalicus
- Class Analgesics; Small molecules
- Mechanism of Action N-type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain; Pain; Postherpetic neuralgia; Stroke
Most Recent Events
- 11 Nov 2013 Discontinued - Phase-I for Pain in Canada (PO)
- 11 Nov 2013 Discontinued - Phase-II for Neuropathic pain in USA (PO)
- 11 Nov 2013 Discontinued - Phase-II for Postherpetic neuralgia in USA (PO)